S'abonner

Pulmonary Hypertension with Left Heart Disease: Prevalence, Temporal Shifts in Etiologies and Outcome - 01/11/17

Doi : 10.1016/j.amjmed.2017.05.003 
Tatyana Weitsman, MD, Giora Weisz, MD, Rivka Farkash, MPH, Marc Klutstein, MD, Adi Butnaru, MD, David Rosenmann, MD, Tal Hasin, MD
 Department of Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel 

Requests for reprints should be addressed to Tal Hasin, MD, Department of Cardiology, Shaare Zedek Medical Center, 12 Byeth Street, Jerusalem 9103102, Israel.Department of CardiologyShaare Zedek Medical Center12 Byeth StreetJerusalem9103102Israel

Abstract

Introduction

Pulmonary hypertension has many causes. While it is conventionally thought that the most prevalent is left heart disease, little information about its proportion, causes, and implications on outcome is available.

Methods

Between 1993 and 2015, 12,115 of 66,949 (18%) first adult transthoracic echocardiograms were found to have tricuspid incompetence gradient ≥40 mm Hg, a pulmonary hypertension surrogate. Left heart disease was identified in 8306 (69%) and included valve malfunction in 4115 (49%), left ventricular systolic dysfunction in 2557 (31%), and diastolic dysfunction in 1776 (21%). Patients with left heart disease, as compared with those without left heart disease, were of similar age, fewer were females (50% vs 63% P <.0001), and they had higher tricuspid incompetence gradient (median 48 mm Hg [interquartile range 43, 55] vs 46 mm Hg [42, 54] P <.0001). In reviewing trends over 20 years, the relative proportions of systolic dysfunction decreased and diastolic dysfunction increased (P for trend <.001), while valve malfunction remained the most prevalent cause of pulmonary hypertension with left heart disease. Independent predictors of mortality were age (hazard ratio [HR] 1.05; 95% CI, 1.04-1.05; P <.0001), tricuspid incompetence gradient (HR 1.02; 95% CI, 1.01-1.02, P <.0001 per mm Hg increase), and female sex (HR 0.87; 95% CI, 0.83-0.91, P <.0001).

Results

Overall, left heart disease was not an independent risk factor for mortality (HR 1.04; 95% CI, 0.99-1.09; P = .110), but patients with left ventricular systolic dysfunction and with combined systolic dysfunction and valve malfunction had increased mortality compared with patients with pulmonary hypertension but without left heart disease (HR 1.30; 95% CI, 1.20-1.42 and HR 1.44; 95% CI, 1.33-1.55, respectively; P <.0001 for both).

Conclusions

Pulmonary hypertension was found to be associated with left heart disease in 69% of patients. Among these patients, valve malfunction and diastolic dysfunction emerged as prominent causes. Left ventricular dysfunction carries additional risk to patients with pulmonary hypertension.

Le texte complet de cet article est disponible en PDF.

Highlights

Echocardiographically tricuspid incompetence gradient of ≥40 mm Hg (pulmonary hypertension surrogate) was found in 18% of first echocardiograms.
Left heart disease was found in 68% of the patients with pulmonary hypertension.
Valve disease is the most common pathology in this group.
Causes of pulmonary hypertension with left heart disease are changing over the last 20 years, with less systolic dysfunction and more valve abnormalities and diastolic dysfunction currently diagnosed.
Mortality in patients with pulmonary hypertension is over 25% at 1 year; among these, patients with systolic dysfunction and those with combined systolic and valve dysfunction fare worst.

Le texte complet de cet article est disponible en PDF.

Keywords : Diastolic dysfunction, Heart valve disease, Survival, Systolic dysfunction, Tricuspid incompetence gradient


Plan


 Funding: No external funding was used for this research.
 Conflict of Interest: None of the authors has any conflict of interest pertinent to the content of this manuscript.
 Authorship: All the authors had access to the data and a role in writing the manuscript.


© 2017  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 130 - N° 11

P. 1272-1279 - novembre 2017 Retour au numéro
Article précédent Article précédent
  • It's Complicated: Parvovirus B19 in Thalassemia
  • Jesse Bertrand, Madison Dennis, Todd Cutler
| Article suivant Article suivant
  • Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
  • Nayan Agarwal, Ankur Jain, Ahmed N. Mahmoud, Rohit Bishnoi, Harsh Golwala, Ashkan Karimi, Mohammad Khalid Mojadidi, Jalaj Garg, Tanush Gupta, Nimesh Kirit Patel, Siddharth Wayangankar, R. David Anderson

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.